Trisalus Life Sciences, INC

TriSalus Life Sciences, Inc. announced the results of its Annual Meeting of Stockholders held on May 14, 2026, including the election of directors and ratification of its independent auditor.

TriSalus Life Sciences reports Q1 2026 results with $8.9M revenue, a $46M equity raise, and revised 2026 revenue guidance.

TriSalus Life Sciences, Inc. reported the upcoming retirement of its Chief of Clinical Operations and the prior appointment of a new Chief Medical Officer.

TriSalus Life Sciences announced the appointment of Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026, to lead medical strategy and clinical leadership.

TriSalus Life Sciences announced robust fourth quarter and full-year 2025 financial results, exceeding revenue guidance and reaffirming its 2026 outlook, bolstered by a recent $46 million public offering.

TriSalus Life Sciences announced the resignation of Dr. Arjun JJ Desai from its Board of Directors and the immediate appointment of Michael P. Stansky, a seasoned investment management and healthcare expert.

TriSalus Life Sciences reports a net income of $1.539 million for Q1 2026, a significant turnaround from a net loss of $10.375 million in Q1 2025, driven by gains in fair value of financial instruments.

TriSalus Life Sciences, Inc. announced a 50.9% revenue increase for the nine months ended September 30, 2025, despite a significantly widened net loss primarily due to non-cash charges from preferred stock conversion.

TriSalus Life Sciences, Inc. reported significant revenue growth in Q2 2025, driven by new product launches, but continues to face substantial net losses and going concern uncertainties.

TriSalus Life Sciences saw a 42% increase in revenue in Q1 2025, driven by increased sales of its TriNav infusion system, but continues to operate at a loss.

TriSalus Life Sciences reports a 41.5% increase in revenue for the third quarter of 2024 compared to the same period in 2023, driven by increased sales of its TriNav infusion system.

TriSalus Life Sciences, Inc. reported a significant 59.7% increase in revenue for the second quarter of 2024, primarily attributed to strong sales of its TriNav Infusion System, despite facing challenges in its clinical development programs.

TriSalus Life Sciences, Inc. reported a 53.4% increase in TriNav revenue for 2025, alongside continued development of its immuno-oncology therapeutic, nelitolimod, while navigating ongoing operating losses and internal control weaknesses.

TriSalus Life Sciences, an oncology-focused medical technology company, reported a significant reduction in net loss and strong revenue growth for the fiscal year ended December 31, 2024, but disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity without further financing.

TriSalus Life Sciences reports a 59% increase in revenue for 2024, driven by its TriNav Infusion System, while continuing to develop its immunotherapeutic, nelitolimod.

TriSalus Life Sciences, Inc. reports progress in its innovative oncology platform, combining drug delivery technology with immunotherapy for liver and pancreatic cancers, while facing financial challenges and navigating a complex regulatory environment.

TriSalus Life Sciences, Inc. reports a transaction where Chief Financial Officer David Patience acquired shares through a tax withholding arrangement.

Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., acquired 3,990 shares through the company's Employee Stock Purchase Plan.

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, Inc., acquired 561 shares of common stock through the Employee Stock Purchase Plan.

TriSalus Life Sciences, Inc. reports a significant stock grant and option award to Chief Medical Officer Richard Henry Marshall.

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, Inc., reported a sale of 543 common shares on May 15, 2026, for tax withholding purposes.

Mats Wahlstrom, a Director at TriSalus Life Sciences, Inc., reported the acquisition of 60,000 common shares.

TriSalus Life Sciences will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to elect directors and ratify the appointment of its independent accounting firm.

TriSalus Life Sciences will hold its 2024 Annual Meeting of Stockholders virtually on August 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.

TriSalus Life Sciences is registering for resale up to 130,805 shares of its common stock issuable upon the exercise of a warrant held by OrbiMed.

Frankenius Equity AB and Paul Frankenius increased their beneficial ownership in TriSalus Life Sciences, Inc. to 14.0% of common stock through a preferred stock exchange.

Key insiders Mats Wahlstrom and Kerry R. Hicks, along with HW Investment Partners, updated their beneficial ownership in TriSalus Life Sciences, Inc. following a completed preferred stock exchange offer.

Frankenius Equity AB, a significant shareholder in TriSalus Life Sciences, Inc., has committed to exchanging its Series A preferred stock for common stock and supporting key corporate governance amendments as part of a new private financing initiative.

First Light Asset Management, LLC and Mathew P. Arens have jointly filed a Schedule 13G, reporting beneficial ownership of 10.74% of TriSalus Life Sciences, Inc. common stock as of June 30, 2026.

James J. Pallotta has reported beneficial ownership of 3,188,711 shares, representing 5.2% of TriSalus Life Sciences, Inc. common stock, including shares underlying warrants.

First Light Asset Management and Mathew P. Arens have reported an 8.75% beneficial ownership stake in TriSalus Life Sciences, Inc. via a Schedule 13G filing.

Utmost Group PLC has reported a beneficial ownership of 3,503,385 shares, representing 5.71% of TriSalus Life Sciences' common stock as of March 31, 2026.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 4.09% beneficial ownership in Trisalus Life Sciences, Inc. as of September 30, 2025.

Utmost Group PLC reported an increased beneficial ownership of 6.79% in TriSalus Life Sciences, Inc. common stock as of September 30, 2025, primarily through a preferred share conversion.